Table 1 SARS-CoV-2 mAbs in clinical development
Sponsor | Product | Clinical stage | Trial ID | Study |
|---|---|---|---|---|
Regeneron/NIAID | REGN-COV2 (REGN10933 + REGN10987; human IgG1 mAbs targeting S protein epitope) | Phase 2/3 | NCT04452318 | 2,000 healthy adults with infected people in household |
Regeneron/NIAID | REGN-COV2 | Phase 2/3 | NCT04426695 | 2,970 hospitalized adults with COVID-19 |
Regeneron/NIAID | REGN-COV2 | Phase 1/2 | NCT04425629 | 2,104 ambulatory patients with COVID-19 |
AbCellera/Eli Lilly/NIH | LY3819253 or LY3819253 + LY3832479 (human IgG1 mAbs targeting S protein epitope) | Phase 3 | NCT04427501 | 800 patients with mild to moderate COVID-19 |
AbCellera/Eli Lilly/NIH | LY3819253 or LY3819253 + LY3832479 | Phase 3 | NCT04497987 | 2,400 healthy staff or residents of skilled nursing facilities |
AbCellera/Eli Lilly/NIH | LY3819253 versus remdesivir (small-molecule nucleotide analog antiviral that blocks viral RNA polymerase) | Phase 3 | NCT04501978 | 10,000 hospitalized patients |
Vir Biotechnology/GlaxoSmithKline | VIR-7831/GSK4182136 (human IgG1 mAb targeting S protein epitope) | Phase 3 | NCT04545060 | 1,360 non-hospitalized patients with COVID-19 at high risk |
BeiGene/Singlomics/Peking University | BGB-DXP593 (human IgG1 mAb targeting S protein epitope) | Phase 2 | NCT04551898 | 180 patients with mild to moderate COVID-19 |
BeiGene/Singlomics/Peking University | BGB-DXP593 | Phase 1 | NCT045332294 | 30 healthy adults 18–60 years olds |
Junshi Biosciences/Institute of Microbiology, Chinese Academy | JS016 (human mAb targeting S protein epitope) | Phase 1 | NCT04441918 | 40 healthy participants 15–45 years old |
Tychan | TY027 | Phase 1 | NCT04429529 | 32 healthy adults 21–50 years old |
Celltrion | CT-P59 (human mAb targeting S protein epitope) | Phase 1 | NCT04525079 | 32 healthy adults 19–55 years old |
Brii Bio/TSB Therapeutics/Tsinghua University | BRII-196 (human mAb targeting S protein epitope) | Phase 1 | NCT04479631 | 12 healthy adults 18–49 years old |
Brii Bio/TSB Therapeutics/Tsinghua University | BRII-198 (human mAb targeting S protein epitope) | Phase 1 | NCT04479644 | 12 healthy adults 18–49 years old |
Sinocelltech/Chinese Academy of Sciences | SCTA01 (humanized mAb targeting S protein epitopes) | Phase 1 | NCT04483375 | 33 healthy adults |
Mabwell (Shanghai) Bioscience | MW33 (human mAb targeting S protein epitope) | Phase 1 | NCT05433048 | 42 healthy adults 18–45 years old |
Sorrento/Mount Sinai | COVI-GUARD/STI-1499 (human mAb targeting S1 subunit of S protein) | Phase 1 | NCT04454398 | 33 hospitalized patients with moderate COVID-19 |
AstraZeneca/Vanderbilt | AZD8895 + AZD1061 (IgG1 human mAbs targeting S protein epitopes) | Phase 1 | NCT04507256 | 48 healthy adults 18–55 years old |
Hengenix Biotech | HLX70 (human mAb targeting S protein epitope) | Phase 1 | NCT04561076 | 24 healthy adults 18–60 years old |
